开云app官网登录入口网页版-官方正版

#BMS#

60篇内容 | 1701人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378691, encodeId=6a6a13e8691e2, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS获得欧盟委员会对CAR-T疗法Breyanzi的支持, objectType=article, longId=295110, objectId=31a329511012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31a329511012, replyNumber=0, likeNumber=96, createdTime=2022-02-05, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31a329511012, moduleTitle=BMS获得欧盟委员会对CAR-T疗法Breyanzi的支持, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=31a329511012)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378690, encodeId=21c613e86909d, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Journal Endovascular Therapy：DCB和BMS治疗股腘动脉病变，术后TLR发生率无差异？, objectType=article, longId=293597, objectId=44cf29359e24, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44cf29359e24, replyNumber=0, likeNumber=128, createdTime=2022-01-09, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44cf29359e24, moduleTitle=Journal Endovascular Therapy：DCB和BMS治疗股腘动脉病变，术后TLR发生率无差异？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=44cf29359e24)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378689, encodeId=b4f613e868983, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, objectType=article, longId=218646, objectId=e1fc218646bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fc218646bf, replyNumber=0, likeNumber=70, createdTime=2021-10-17, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fc218646bf, moduleTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e1fc218646bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378688, encodeId=2c4113e86882f, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准, objectType=article, longId=209107, objectId=d5a420910e55, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5a420910e55, replyNumber=0, likeNumber=63, createdTime=2021-03-29, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5a420910e55, moduleTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d5a420910e55)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378687, encodeId=787e13e868710, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=FDA接受BMS在梗阻性肥厚性心肌病（oHCM）中使用Mavacamten的申请, objectType=article, longId=208823, objectId=6828208823c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6828208823c0, replyNumber=0, likeNumber=131, createdTime=2021-03-23, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6828208823c0, moduleTitle=FDA接受BMS在梗阻性肥厚性心肌病（oHCM）中使用Mavacamten的申请, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6828208823c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=131亿美元！BMS完成对MyoKardia的收购，获得心血管特效药mavacamten, objectType=article, longId=203521, objectId=7249203521e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7249203521e8, replyNumber=0, likeNumber=72, createdTime=2020-11-20, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7249203521e8, moduleTitle=131亿美元！BMS完成对MyoKardia的收购，获得心血管特效药mavacamten, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7249203521e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378685, encodeId=41b313e8685d8, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=J Neurointerv Surg：药物涂层球囊治疗冠状动脉新生病变的效果并不劣于BMS或DES, objectType=article, longId=203301, objectId=ffa520330166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffa520330166, replyNumber=0, likeNumber=85, createdTime=2020-11-14, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffa520330166, moduleTitle=J Neurointerv Surg：药物涂层球囊治疗冠状动脉新生病变的效果并不劣于BMS或DES, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ffa520330166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378684, encodeId=5ce913e868448, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, objectType=article, longId=202961, objectId=601d202961a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601d202961a3, replyNumber=0, likeNumber=114, createdTime=2020-11-07, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601d202961a3, moduleTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=601d202961a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378683, encodeId=f60613e8683b9, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=J Tissue Eng Regen Med：BMSCs衍生的外泌体对炎症和成骨的免疫调节作用, objectType=article, longId=201818, objectId=f0542018187a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0542018187a, replyNumber=0, likeNumber=66, createdTime=2020-10-09, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0542018187a, moduleTitle=J Tissue Eng Regen Med：BMSCs衍生的外泌体对炎症和成骨的免疫调节作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f0542018187a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378682, encodeId=b6a713e868285, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Cell Transplant：研究揭示αCGRP影响BMSCs迁移和成骨的机制, objectType=article, longId=201598, objectId=1d1c20159867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d1c20159867, replyNumber=0, likeNumber=58, createdTime=2020-10-05, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d1c20159867, moduleTitle=Cell Transplant：研究揭示αCGRP影响BMSCs迁移和成骨的机制, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1d1c20159867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378681, encodeId=da3e13e8681c9, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Biomed Res Int：研究发现镁通过调整骨免疫调控增强BMSCs的成骨作用, objectType=article, longId=201596, objectId=2ed320159663, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ed320159663, replyNumber=0, likeNumber=78, createdTime=2020-10-05, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ed320159663, moduleTitle=Biomed Res Int：研究发现镁通过调整骨免疫调控增强BMSCs的成骨作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2ed320159663)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378680, encodeId=413d13e86802b, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……, objectType=article, longId=200934, objectId=8f8c200934f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8c200934f5, replyNumber=0, likeNumber=100, createdTime=2020-09-21, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8c200934f5, moduleTitle=吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8f8c200934f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378679, encodeId=758313e8679ac, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, objectType=article, longId=195725, objectId=0297195e2587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0297195e2587, replyNumber=0, likeNumber=77, createdTime=2020-06-13, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0297195e2587, moduleTitle=BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0297195e2587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378678, encodeId=603d13e86787e, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Stem Cells Int：PDGF-BB可增强BMSC的成骨和血管生成能力促进骨再生, objectType=article, longId=194951, objectId=bd5d19495199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd5d19495199, replyNumber=0, likeNumber=71, createdTime=2020-05-31, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd5d19495199, moduleTitle=Stem Cells Int：PDGF-BB可增强BMSC的成骨和血管生成能力促进骨再生, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bd5d19495199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378677, encodeId=a50113e867739, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, objectType=article, longId=194364, objectId=22021943645c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22021943645c, replyNumber=0, likeNumber=108, createdTime=2020-05-20, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22021943645c, moduleTitle=肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=22021943645c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378676, encodeId=b35d13e867604, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, objectType=article, longId=188791, objectId=aa9f188e91bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa9f188e91bf, replyNumber=0, likeNumber=68, createdTime=2020-02-27, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa9f188e91bf, moduleTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aa9f188e91bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378675, encodeId=e32513e86756c, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=JAMA Oncol：BMS-986156单药或联合纳武单抗治疗晚期实体肿瘤, objectType=article, longId=183395, objectId=5a5318339506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a5318339506, replyNumber=0, likeNumber=56, createdTime=2019-11-23, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a5318339506, moduleTitle=JAMA Oncol：BMS-986156单药或联合纳武单抗治疗晚期实体肿瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5a5318339506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378674, encodeId=3fa313e867445, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的Opdivo/Yervoy组合治疗肝细胞癌，获得FDA的优先审查, objectType=article, longId=183122, objectId=309218312237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=309218312237, replyNumber=0, likeNumber=93, createdTime=2019-11-19, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=309218312237, moduleTitle=BMS的Opdivo/Yervoy组合治疗肝细胞癌，获得FDA的优先审查, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=309218312237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378673, encodeId=0dcf13e86737c, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=62, createdTime=2019-10-25, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378672, encodeId=93cd13e8672ab, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS和辉瑞宣布与Fitbit合作推动房颤可穿戴设备的及时诊断, objectType=article, longId=181604, objectId=b52018160411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b52018160411, replyNumber=0, likeNumber=86, createdTime=2019-10-21, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b52018160411, moduleTitle=BMS和辉瑞宣布与Fitbit合作推动房颤可穿戴设备的及时诊断, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b52018160411)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

BMS

2020-05-29

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS获得欧盟委员会对CAR-T疗法Breyanzi的支持

2022-02-05

canlab (审核中...)

前往app查看评论内容

#BMS#

Journal Endovascular Therapy：DCB和BMS治疗股腘动脉病变，术后TLR发生率无差异？

2022-01-09

canlab (审核中...)

前往app查看评论内容

#BMS#

J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差

2021-10-17

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准

2021-03-29

canlab (审核中...)

前往app查看评论内容

#BMS#

FDA接受BMS在梗阻性肥厚性心肌病（oHCM）中使用Mavacamten的申请

2021-03-23

canlab (审核中...)

前往app查看评论内容

#BMS#

131亿美元！BMS完成对MyoKardia的收购，获得心血管特效药mavacamten

2020-11-20

canlab (审核中...)

前往app查看评论内容

#BMS#

J Neurointerv Surg：药物涂层球囊治疗冠状动脉新生病变的效果并不劣于BMS或DES

2020-11-14

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast

2020-11-07

canlab (审核中...)

前往app查看评论内容

#BMS#

J Tissue Eng Regen Med：BMSCs衍生的外泌体对炎症和成骨的免疫调节作用

2020-10-09

canlab (审核中...)

前往app查看评论内容

#BMS#

Cell Transplant：研究揭示αCGRP影响BMSCs迁移和成骨的机制

2020-10-05

canlab (审核中...)

前往app查看评论内容

#BMS#

Biomed Res Int：研究发现镁通过调整骨免疫调控增强BMSCs的成骨作用

2020-10-05

canlab (审核中...)

前往app查看评论内容

#BMS#

吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……

2020-09-21

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS的PD-1单抗Opdivo，获得FDA批准用于晚期食道鳞状细胞癌

2020-06-13

canlab (审核中...)

前往app查看评论内容

#BMS#

Stem Cells Int：PDGF-BB可增强BMSC的成骨和血管生成能力促进骨再生

2020-05-31

canlab (审核中...)

前往app查看评论内容

#BMS#

肺癌一线免疫治疗！BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症，治疗转移性非小细胞肺癌患者!

2020-05-20

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS的PD-1单抗Opdivo首次获批治疗食道癌

2020-02-27

canlab (审核中...)

前往app查看评论内容

#BMS#

JAMA Oncol：BMS-986156单药或联合纳武单抗治疗晚期实体肿瘤

2019-11-23

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS的Opdivo/Yervoy组合治疗肝细胞癌，获得FDA的优先审查

2019-11-19

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功

2019-10-25

canlab (审核中...)

前往app查看评论内容

#BMS#

BMS和辉瑞宣布与Fitbit合作推动房颤可穿戴设备的及时诊断

2019-10-21

科室
- - 订阅+
  - 更多科室
工具
服务